FDA Clearance Tracker · K260437
Valvuloplasty Balloon Catheter (ValvuloPro)
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 20, 2026
Substantially Equivalent
Time to decision
37 days
Received Feb 11, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K260437
- Device name
- Valvuloplasty Balloon Catheter (ValvuloPro)
- Applicant
- Dongguan TT Medical, Inc.
- Applicant location
- Dongguan, CN
- Received
- Feb 11, 2026
- Decided
- Mar 20, 2026
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Balloon Aortic Valvuloplasty (OZT)
- Device class
- Class II
- Regulation
- 21 CFR 870.1255
- Specialty
- CardiologyInterventional Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OZT. The earliest in FDA's data is DEN080015, decided Jun 11, 2012.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K260437
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Dongguan TT Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K240967 · Decided Jul 31, 2024 · 113 days after receipt
Device type: Balloon Aortic Valvuloplasty (OZT) · Cardiology
K231814 · Decided Oct 12, 2023 · 113 days after receipt
Device type: Balloon Aortic Valvuloplasty (OZT) · Cardiology
K230374 · Decided Jun 29, 2023 · 136 days after receipt
Device type: Catheters, Transluminal Coronary Angioplasty, Percutaneous (LOX) · Cardiology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.